📊 ASTH Key Takeaways
Is Astrana Health, Inc. (ASTH) a Good Investment?
Astrana Health demonstrates strong revenue growth of 56.4% YoY with positive free cash flow of $104.5M, indicating operational expansion capability. However, extremely thin profit margins (0.7% net, 2.5% operating) and concerning gross margin collapse to 0.0% suggest severe pricing pressures, cost absorption issues, or acquisition accounting effects that warrant investigation before establishing conviction.
Astrana Health is showing strong top-line momentum, with revenue up 56.4% year over year and positive free cash flow generation, which suggests the business is scaling and still converting earnings into cash. However, profitability quality is weak: net income declined, diluted EPS fell sharply, margins remain very thin, and leverage is meaningful, so the current fundamental profile looks mixed rather than clearly strong.
Why Buy Astrana Health, Inc. Stock? ASTH Key Strengths
- Strong revenue growth of 56.4% YoY indicating market demand and successful business expansion
- Positive free cash flow of $104.5M with 3.3% FCF margin showing cash generation capability
- Adequate liquidity with 1.40x current ratio and $429.5M cash position relative to operations
- Interest coverage ratio of 4.9x demonstrates ability to service debt obligations
- Revenue growth is very strong at 56.4% year over year, indicating expanding scale and demand.
- Liquidity appears adequate, with $429.47M in cash and 1.40x current and quick ratios.
- Cash generation is positive, with $114.60M in operating cash flow and $104.49M in free cash flow.
ASTH Stock Risks: Astrana Health, Inc. Investment Risks
- Gross margin at 0.0% is severely abnormal and indicates potential acquisition-related accounting, service delivery cost problems, or unsustainable pricing dynamics
- Net income declined 6.6% YoY despite 56.4% revenue growth, showing profitability deterioration amid expansion
- Diluted EPS dropped 48.9% YoY signaling significant per-share value destruction despite top-line growth
- High leverage with 1.27x debt/equity ratio and $990.9M long-term debt against $779.3M equity
- Extremely low ROE of 2.9% and ROA of 1.0% indicate poor capital efficiency and asset utilization
- Profitability is thin, with just 2.5% operating margin and 0.7% net margin, leaving limited cushion if costs rise.
- Earnings quality is under pressure, with net income down 6.6% and diluted EPS down 48.9% year over year.
- Leverage is elevated, with $990.90M of long-term debt, 1.27x debt-to-equity, and only moderate 4.9x interest coverage.
Key Metrics to Watch
- Gross margin trajectory and return to positive levels (investigate 0.0% anomaly)
- Operating margin expansion vs. revenue growth sustainability
- Free cash flow conversion rate and capital allocation discipline
- Debt reduction pathway and leverage ratio trend
- Year-over-year net income and EPS growth inflection
- Operating and net margin improvement as revenue growth scales
- Debt reduction and interest coverage trend
Astrana Health, Inc. (ASTH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.3% FCF margin may limit capital allocation flexibility.
ASTH Profit Margin, ROE & Profitability Analysis
ASTH vs Services Sector: How Astrana Health, Inc. Compares
How Astrana Health, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Astrana Health, Inc. Stock Overvalued? ASTH Valuation Analysis 2026
Based on fundamental analysis, Astrana Health, Inc. shows some fundamental concerns relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Astrana Health, Inc. Balance Sheet: ASTH Debt, Cash & Liquidity
ASTH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Astrana Health, Inc.'s revenue has grown significantly by 311% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.29 reflects profitable operations.
ASTH Revenue Growth, EPS Growth & YoY Performance
ASTH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $478.7M | $373.0K | $0.01 |
| Q2 2025 | $486.3M | $9.4M | $0.19 |
| Q1 2025 | $404.4M | $6.7M | $0.14 |
| Q3 2024 | $348.2M | $16.1M | $0.33 |
| Q2 2024 | $348.2M | $13.2M | $0.28 |
| Q1 2024 | $337.2M | $13.1M | $0.28 |
| Q3 2023 | $317.0M | $22.1M | $0.47 |
| Q2 2023 | $269.7M | $12.0M | $0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Astrana Health, Inc. Dividends, Buybacks & Capital Allocation
ASTH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Astrana Health, Inc. (CIK: 0001083446)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ASTH
What is the AI rating for ASTH?
Astrana Health, Inc. (ASTH) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ASTH's key strengths?
Claude: Strong revenue growth of 56.4% YoY indicating market demand and successful business expansion. Positive free cash flow of $104.5M with 3.3% FCF margin showing cash generation capability. ChatGPT: Revenue growth is very strong at 56.4% year over year, indicating expanding scale and demand.. Liquidity appears adequate, with $429.47M in cash and 1.40x current and quick ratios..
What are the risks of investing in ASTH?
Claude: Gross margin at 0.0% is severely abnormal and indicates potential acquisition-related accounting, service delivery cost problems, or unsustainable pricing dynamics. Net income declined 6.6% YoY despite 56.4% revenue growth, showing profitability deterioration amid expansion. ChatGPT: Profitability is thin, with just 2.5% operating margin and 0.7% net margin, leaving limited cushion if costs rise.. Earnings quality is under pressure, with net income down 6.6% and diluted EPS down 48.9% year over year..
What is ASTH's revenue and growth?
Astrana Health, Inc. reported revenue of $3.2B.
Does ASTH pay dividends?
Astrana Health, Inc. pays dividends, with $7.9M distributed to shareholders in the trailing twelve months.
Where can I find ASTH SEC filings?
Official SEC filings for Astrana Health, Inc. (CIK: 0001083446) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ASTH's EPS?
Astrana Health, Inc. has a diluted EPS of $0.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ASTH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Astrana Health, Inc. has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ASTH stock overvalued or undervalued?
Valuation metrics for ASTH: ROE of 2.9% (sector avg: 16%), net margin of 0.7% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy ASTH stock in 2026?
Our dual AI analysis gives Astrana Health, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ASTH's free cash flow?
Astrana Health, Inc.'s operating cash flow is $114.6M, with capital expenditures of $10.1M. FCF margin is 3.3%.
How does ASTH compare to other Services stocks?
Vs Services sector averages: Net margin 0.7% (avg: 10%), ROE 2.9% (avg: 16%), current ratio 1.40 (avg: 1.5).